In vivo, formononetin was demonstrated to be neuroprotective in the APP/PS1 mice (a mouse model of AD), shown by marked functional improvements in spatial learning and memory in Morris water maze test (Fei et al., 2018). This evidence concerns the gene APP and Alzheimer disease.